On January 24, 2010 Joe Feshbach (picture- here with his wife Cindy) published an article on his Instablog at Seeking Alpha, written by his friend, former investment banker and author of the book "Lost Star of Myth and Time"- Walter Cruttenden. An absolute classic for believers in Cytori technology. Joe was one of those believers and after attending the first Cellsociety annual meeting in San Diego in February 2011 decided with his brother Matt and other investors, to put his money where his "believes" were and started to organize the construction of a cardiac clinic on the Bahama´s using Cytori tech- i.e.Celution One. Unfortunately Joe suffered a massive heart attack on August 8 2011 whilst on a biketrip and never could see his plans come to fruition.

On this spring afternoon, the 44-year-old CEO of San Diego- based biotech company Cytori Therapeutics pulls out his laptop, launches a PowerPoint presentation, and there they are: conical and cantaloupy. As through Ds, beige and pink and taupe and tan, more breasts than you might see in a women's locker room, never mind in the middle of a lunch table.

A passing waiter does a double take at this lively slide show, but Calhoun is oblivi­ous. He's talking excitedly about how these women's bodies led him and his team of sci­entists to a discovery in tissue engineer­ing, a process that could well be one of the most momentous medical advances of the 21st century: the use of stemcells..... specifically stem-cell enriched adipose (fat) tissue—to enhance, heal, and rebuild injured or damaged organs.

Part II- "These things have gone through the ringer in choosing a name," says biomechan-ical engineer Kent Leach of UC Davis, who has used whatever-they-are to treat bone cysts in racehorses. A stem cell, by definition, is able to differentiate into any of the 200-plus kinds of cells in the human body, just as the cells of a days-old embryo can (and do). Cytori's are unlikely to ever show that range of differentiation. But they can differentiate into fat, bone, and muscle -among other tissues—depending on which signaling molecules they are exposed to. In a petri dish, the scientists provide those "this is what you will be when you grow up" molecules. In nature—that is, an embryo in a womb—biology somehow does.

The biotech company has had successful clinical trials yet is unloved by the market. Here's why investors should start a position now.

Written by James Anderson

Typically, early-stage biotech companies are considered to have a binary outcome. If successful with the first product that enters clinical trials the company moves on to raise more money through stock sales, enter a partnership with a large pharmaceutical company, or sell the company. In each case, investors do well. However, if the first product fails in its clinical trial, there is a good chance the company will run out of money and fail. Hence, it’s binary -- all or nothing.

Stem cell therapies have been garnering significant attention as the field of regenerative medicine starts to evolve. As one would expect, there are a number of start-up biotech companies in the field.